评估蒙特利尔认知评估在系统性红斑狼疮患者认知障碍筛查中的效用
研究纳入285例成人系统性红斑狼疮患者,以美国风湿病学会神经心理成套测验为参照,评估蒙特利尔认知评估筛查认知障碍的效度。蒙特利尔认知评估的曲线下面积为0.66,判界值26时敏感度50%、特异度69%,判界值28时敏感度80%、特异度45%;将其加入自动化神经心理评估指标仅使曲线下面积提高2.5%。作者认为蒙特利尔认知评估的并发效度不足,不支持下述用途:将其作为系统性红斑狼疮患者认知障碍的筛查工具。
要点
- 以美国风湿病学会神经心理成套测验为参照,蒙特利尔认知评估识别认知障碍的曲线下面积为0.66。
- 判界值26时敏感度50%、特异度69%;判界值28时敏感度80%、特异度45%。
- 蒙特利尔认知评估加入自动化神经心理评估指标仅使曲线下面积提高2.5%。
核心结论
- 蒙特利尔认知评估不具备足够的并发效度,不能准确识别系统性红斑狼疮患者的认知障碍。
- 蒙特利尔认知评估特异度低,可能导致过度诊断及患者担忧。
- 将蒙特利尔认知评估加入自动化神经心理评估指标并未实质性提高后者的准确性。
- 上述结果不支持将蒙特利尔认知评估用作系统性红斑狼疮患者认知障碍的筛查工具。
研究设计与样本
- 共285例成人系统性红斑狼疮患者接受美国风湿病学会神经心理成套测验、蒙特利尔认知评估和自动化神经心理评估指标检查。
- 美国风湿病学会神经心理成套测验中,≥2个领域Z评分≤-1.5者判定为认知障碍。
- 计算曲线下面积及敏感度、特异度,并采用判别函数分析评估蒙特利尔认知评估区分认知障碍、未定认知障碍与非认知障碍患者的能力。
主要发现
- 与美国风湿病学会神经心理成套测验相比,蒙特利尔认知评估未能准确识别认知障碍,曲线下面积为0.66。
- 判界值26时敏感度50%、特异度69%;判界值28时敏感度80%、特异度45%。
- 蒙特利尔认知评估识别认知障碍状态的能力低。
- 蒙特利尔认知评估加入自动化神经心理评估指标后,曲线下面积仅提高2.5%。
关键数值与推荐
- 美国风湿病学会神经心理成套测验判定认知障碍的标准为≥2个领域Z评分≤-1.5。
- 蒙特利尔认知评估判界值26:敏感度50%、特异度69%。
- 蒙特利尔认知评估判界值28:敏感度80%、特异度45%。
- 蒙特利尔认知评估对比美国风湿病学会神经心理成套测验的曲线下面积为0.66。
- 蒙特利尔认知评估加入自动化神经心理评估指标后曲线下面积提高2.5%。
临床怎么用
- 原文结论指出,上述结果不支持将蒙特利尔认知评估用作系统性红斑狼疮患者认知障碍的筛查工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Screening for cognitive impairment (CI) in systemic lupus erythematosus (SLE) relies on the American College of Rheumatology (ACR) neuropsychological battery (NB). By studying the concurrent criterion validity, our goal was to assess the Montreal Cognitive Assessment (MoCA) as a screening tool for CI compared to the ACR-NB and to evaluate the added value of the MoCA to the Automated Neuropsychological Assessment Metrics (ANAM). METHODS: A total of 285 adult SLE patients were administered the ACR-NB, MoCA, and ANAM. For the ACR-NB, patients were classified as having CI if there was a Z score of ≤-1.5 in ≥2 domains. The area under the curve (AUC) and sensitivities/specificities were determined. A discriminant function analysis was applied to assess the ability of the MoCA to differentiate between CI, undetermined CI, and non-CI patients. RESULTS: CI was not accurately identified by the MoCA compared to the ACR-NB (AUC of 0.66). Sensitivity and specificity were poor at 50% and 69%, respectively, for the cutoff of 26, and 80% and 45%, respectively, for the cutoff of 28. The MoCA had a low ability to identify CI status. The addition of the MoCA to the ANAM led to improvement on the AUC by only 2.5%. CONCLUSION: The MoCA does not have adequate concurrent criterion validity to accurately identify CI in patients with SLE. The low specificity of the MoCA may lead to overdiagnosis and concern among patients. Adding the MoCA to the ANAM does not substantially improve the accuracy of the ANAM. These results do not support using the MoCA as a screening tool for CI in patients with SLE.
引用
- Tayer-Shifman OE, Yuen K, Green R, et al. Assessing the Utility of the Montreal Cognitive Assessment in Screening for Cognitive Impairment in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022. PMID: 35724303. doi:10.1002/acr.24971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。